AVDL
Avadel Pharmaceuticals plc [AVDL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AVDL Stock Summary
Top 10 Correlated ETFs
AVDL
Top 10 Correlated Stocks
AVDL
In the News
AVDL Financial details
Company Rating
-
Market Cap
1.44B
Income
-160.28M
Revenue
27.96M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
154
Optionable
No
Shortable
Yes
Earnings
04 Mar 2024
P/E
-8.79
Forward P/E
-
PEG
7.46
P/S
173.73
P/B
12.68
P/C
-
P/FCF
-12.68
Quick Ratio
2.97
Current Ratio
3.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.02
EPS next Y
-
EPS next Q
-
EPS this Y
-12.66%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
17.58%
Revenue last 5Y
-13.93%
Revenue Q/Q
177.35%
EPS Q/Q
-26.83%
-
-
-
-
SMA20
-1.39%
SMA50
-24.93%
SMA100
-39.3%
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
-328%
ROC
-0.91%
Gross Margin
98%
Oper. Margin
-1598%
Profit Margin
-1868%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.5-17.47
52W High
-53.47%
52W Low
-12.11%
RSI
43.28
Rel Volume
0.61
Avg Volume
1.2M
Volume
731.68K
Perf Week
-0.75%
Perf Month
-0.38%
Perf Quarter
-43.3%
Perf Half Y
-45.41%
-
-
-
-
Beta
1.632
-
-
Volatility
0.14%, 0.45%
Prev Close
0.38%
Price
7.91
Change
-0.5%
Company Profile
- Volume Average 1.2M
- Market Capitalization 1.44B
- Employee 154
- CEO Mr. Gregory J. Divis Jr.
- Headquarters Dublin,IE
- IPO Date 1996-06-07
-
Website
https://www.avadel.com 
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
